To evaluate the economic impact of prevention against the care of diseases caused by the Aedes Aegypt mosquito. This is the theme of one of the posters that will be presented at the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Latam. This year's edition will be held in the city of São Paulo (BR), from September 15 to 17. The annual ISPOR meeting is one of the most important channels of scientific dissemination on pharmacoeconomics and results research.
The poster Aedes Aegypt: economic impact of prevention versus palliation of diseases caused by the mosquito is authored by Evidências – Kantar Health. The study will evaluate the expenditures of the Brazilian government has during these outbreaks caused by the mosquito, comparing them with the expenditures in prevention campaigns. Aedes Aegypt is the vector responsible for the transmission of four diseases that have had major outbreaks recently in Brazil: dengue, zika, chikungunya and yellow fever. According to the World Health Organization (WHO), dengue fever is endemic in more than 128 countries, with about 3.8 million people at risk. The largest outbreak in Brazil occurred in 2015, with approximately two million reported cases and over 900 deaths according to MoH data.
It will be the third time that ISPOR conference is held in Brazil, which is crucial to draw attention to the scenario of the country's health system and its contribution to scientific research in the world. “The importance of having ISPOR in Brazil is that it brings the opportunity to make a local discussion about the processes of incorporation of new technologies, both in Brazil and in Latin America”, says Otávio Clark, CEO of Evidências – Kantar Health.
Evidências – Kantar Health participates annually in ISPOR meetings with various exhibits and podiums. Only at the conference held in Santiago (CHI) in 2015, Evidências participated with 19 posters and had four of them awarded.
ISPOR is one of the most important scientific channels for dissemination of pharmacoeconomics and outcomes research. Besides being a public non-profit organization for educational and scientific purposes, the objective of ISPOR is promoting the science of pharmacoeconomics and the research results and facilitating the translation of this research into useful information for decision makers in the area of healthcare. The society has more than 6,500 members in 100 countries and 62 regional chapters with over 4,800 members. ISPOR promotes three annual meetings, conducted in North America, Europe, and Latin America or Asia.